Posted by Michael Wonder on 14 Mar 2019
FDA grants Purdue Pharma’s nalmefene hydrochloride injection fast track designation for the emergency treatment of known or suspected opioid overdose
13 March 2019 - Committed to advancing solutions to the opioid public health crisis, Purdue will not profit from nalmefene hydrochloride.
Purdue Pharma today announced that the U.S. FDA has granted fast track designation to nalmefene hydrochloride injection, the company’s investigational opioid antagonist for the emergency treatment of known or suspected opioid overdose.
This designation comes at a time when overdose deaths due to opioids continue to rise, driven by abuse of extremely potent and long-lasting synthetic opioid agonists, particularly illicitly manufactured fentanyl and its analogues.
